LOS ANGELES--(BUSINESS WIRE)--SiDMAP, LLC, a leading provider of metabolic profiling and biomarker development services to the pharmaceutical, academic, governmental, and biotechnology industries, announced today the publication of its 13C Isotopolome Wide Association Study (IWAS) matrix in the official journal of the Federation of American Societies for Experimental Biology in collaboration with scientists at the University Of Utah School Of Medicine.
SiDMAP presents its positional 13C labeling findings in multiple metabolic products of diverse samples from a single 13C labeled glucose tracer in animals with dietary iron overload. The work is published in the March 2013 issue of the FASEB Journal and titled “Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice”. [FASEB J. 2013 Mar 20; PMID: 23515442]
It has been known from previous studies that iron exerts significant effects involving several tissues to disturb glucose homeostasis and pose as diabetes risk. “This system-wide association study (SWAS) using 13C tracer links iron with activation of AMP-dependent kinase in liver and muscle, with resulting modulation of fat and glucose metabolism. SWAS illuminated this primary regulatory action in a complex system,” said Dr. Donald A. McClain, the lead investigator of the Study.
“Single 13C tracer applications that reveal correlations in the metabolic networks among multiple organs, at various time points and drug doses, using isotopolome-wide associations, will eventually replace multiple tracers but limited product distribution pattern studies to simplify System’s Biology,” said Laszlo G. Boros, M.D., SiDMAP’s Chief Scientific Advisor.
SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug’s mechanism of action and disease states. SiDMAP’s unique tracer technology measures metabolic pathway flux to gain unique insights into cell function. A SiDMAP assay provides clients with an accurate, dynamic metabolic analysis of a compound’s biological impact in both in vitro and in vivo systems, before a company spends millions more on development and clinical trials. SiDMAP is headquartered in Los Angeles, California.